Celcuity Inc.

CELC· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$69.16-0.20%

2026-10-30

Financials

Valuation Metrics

Celcuity Inc.'s Market Cap is $3.37B. At end of 2025 it was $5.24B. Ranked #1617 of 3,116 in US market (top 52%), #568 of 1,472 on NASDAQ (top 39%), #94 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 35%) by Market Cap.

Investment Metrics(as of 2026-10-30)

Metric	Value	Rank
Size
Market Cap	$3.37B	US#1,617/3,116 Sec#94/265
Revenue	$0.00	US#2,859/3,116 Sec#193/265
Net Income	$-226M	US—/3,116 Sec—/265
Total Assets	$828M	US#2,551/3,116 Sec#116/265
Net Assets	$-13M	US#2,920/3,116 Sec#243/265
Employees	155	US#2,526/3,116 Sec#142/265
Value
FCF Yield	-5.70%	US—/3,116 Sec—/265
Profitability
ROA	-27.35%	US#2,860/3,116 Sec#150/265
Financial Health
Total Debt	$754M	US#1,668/3,116 Sec#54/265
FCF	$-192M	US#2,772/3,116 Sec#205/265
Cash	$182M	US#1,802/3,116 Sec#117/265
Current Ratio	8.93x	US#283/3,116 Sec#84/265
Performance
1Y Return	-12.41%	US#2,031/3,116 Sec#164/265
1M Return	-13.03%	US#2,586/3,116 Sec#194/265
From 52W High	-54.20%	US#2,751/3,116 Sec#212/265
1Y MDD	-60.97%	US#2,752/3,116 Sec#208/265
Trading
Volume	567,582 shares	US#1,766/3,116 Sec#179/265
Trading Value	$39M	US#1,288/3,116 Sec#92/265
Per Share
EPS	$-4.64	US—/3,116 Sec—/265
BPS	$-0.26	US—/3,116 Sec—/265

Company Info

CEO Brian F. Sullivan

Employees 155

HQ Minneapolis, US

Website https://www.celcuity.com

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.